Does MTRR rs1801394 GG cause functional B12 deficiency with macrocytosis despite normal serum B12 and folate levels?

The MTRR rs1801394 GG polymorphism represents a significant genetic factor in the regulation of the methionine cycle. Evidence indicates that this genotype can lead to a state of "functional" vitamin B12 deficiency, where the cellular utilization of the vitamin is impaired even if circulating blood levels appear normal.

Clinical and effectiveness evidence

The MTRR rs1801394 GG genotype (also known as c.66A>G) is characterized by an isoleucine-to-methionine substitution (Ile22Met) that reduces the efficiency of the methionine synthase reductase enzyme.

• Enzymatic Impact: Research indicates that the GG variant is associated with a lower maximum reaction velocity (Vmax) in enzyme assays, meaning the enzyme works more slowly than the wild-type (AA) version.
• Hematological Markers: Clinical studies of patients with megaloblastic changes have shown that those with the GG or AG genotypes often exhibit more pronounced abnormalities in red blood cell indices, such as elevated Mean Corpuscular Volume (MCV) and lower hemoglobin, compared to those with the AA genotype.
• Serum vs. Cellular Levels: While individuals with this genotype may have serum vitamin B12 and folate levels within standard reference ranges, they can still experience functional deficits. This is because serum tests measure what is circulating in the blood, whereas the MTRR enzyme governs how B12 is actually used inside the cells to support DNA synthesis and methylation.

Mechanistic explanations

The biological basis for this claim rests on the role of MTRR in the reductive activation of methionine synthase (MTR).

• Cofactor Regeneration: MTR requires vitamin B12 in the form of methylcobalamin to convert homocysteine to methionine. During this cycle, the B12 cofactor occasionally becomes oxidized to an inactive state [cob(II)alamin].
• MTRR Function: MTRR is the specific enzyme responsible for "recharging" this inactive B12 back into methylcobalamin using NADPH as an electron donor.
• Functional Deficiency: When MTRR function is reduced (as in the GG genotype), the rate of B12 reactivation slows down. This creates a bottleneck in the methionine cycle, leading to "trapped" folate and impaired DNA synthesis in rapidly dividing cells, such as red blood cell precursors in the bone marrow.
• Macrocytosis: This impairment in DNA synthesis causes erythroid precursors to undergo fewer divisions while their cytoplasm continues to grow, resulting in the enlarged red blood cells (high MCV) and varied cell sizes (high RDW) characteristic of megaloblastic changes.

Bottom line

The MTRR rs1801394 GG genotype reduces the efficiency of B12 recycling, which can lead to elevated MCV and RDW as signs of functional B12 deficiency, even when standard blood tests show normal vitamin levels. This suggests that for GG carriers, "normal" serum B12 may not reflect adequate cellular B12 activity.